Major Health to put new $89 million hospital along I-74
Major Health Partners will construct the new hospital on the north edge of Shelbyville, after nearly a decade of shifting services to that location. Construction could begin next month.
Health Care Businesses
Articles
Testosterone drugs need study on heart risks, FDA panel says
Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.
Community Health plans $175M expansion of East facilities
Community executives said the investment and projects, which will begin this fall and extend over several years, prove their long-term commitment to the east side of the city.
FDA set to review testosterone-boosting drug usage
Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Lilly execs make pitch for local preschool education
Eli Lilly and Co. executives on Friday repeated their plea to local businesses to support early childhood education, highlighting the work force development and crime-reduction benefits associated with the effort.
Lilly cancer drug fares well in late-stage study
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
Lilly receives European marketing OK for new insulin
European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent-infringement litigation with French rival Sanofi.
Lilly says new insulin fares better than rival’s in late-stage tests
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Feds: AIT’s Evans ‘unjustly enriched’ himself in sale to employees
Just three months before the parent company of AIT Laboratories was sold in 2009 to its employees for $90 million, it was appraised for $17.1 million, according to a U.S. Department of Labor lawsuit.
Lilly, partner lose appeal to overturn $9 billion Actos court award
Takeda Pharmaceutical Co. and Eli Lilly and Co. lost a bid to have a judge throw out a combined $9 billion punitive-damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine.
Blood Center retrenches after losing major clients to Red Cross
The Indiana Blood Center is set to lose more than one-third of its revenue early next year, as three hospital systems bolt for cheaper prices offered by the American Red Cross.
Franciscan cuts its way to higher profits
Franciscan Alliance, which operates three hospitals in the Indianapolis area, is seeing fewer patients this year but is making more money due to expense cuts.
EMS service to lay off 361 workers in Indiana
Rural/Metro Corp. says the changing health care landscape and the challenges of covering rural communities are forcing it to end its area ambulance services. It’s also closing a billing operations center in Indianapolis.
Lilly wins tentative approval for diabetes drug
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.
Cardinal Health unit seeks tax breaks for local drug facility
A subsidiary of Dublin, Ohio-based Cardinal Health Inc. is seeking tax breaks from the city of Indianapolis to help it open a $14.4 million local drug-production facility that would employ 85 workers by 2017.
Lilly among those eyeing antibiotic maker Cubist, analyst says
The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020.
Eli Lilly to close Terre Haute animal enzyme plant
The plant closure will affect 23 plant employees, all of whom will be offered comparable positions at a Lilly plant near Clinton that employs about 500 workers.
Struggling hospital finds buyer, enters bankruptcy protection
Bloomington’s Monroe Hospital, which has had a close relationship with Indianapolis-based St. Vincent Health, filed for bankruptcy reorganization on Friday and plans to sell its business to a Canadian operator.
FDA approves Lilly, Boehringer diabetes drug
The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes who also are trying to control their condition with diet and exercise.